A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis

NCT00320216 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Ustekinumab
DRUG: Placebo

Sponsor

Centocor, Inc.